133 related articles for article (PubMed ID: 32922551)
1. Risk Prediction for Locoregional Recurrence in Epidermal Growth Factor Receptor-Mutant Stage III-pN2 Lung Adenocarcinoma after Complete Resection: A Multi-center Retrospective Study.
Li QW; Qiu B; Liang WH; Wang JY; Hu WM; Zhang T; Xu SB; López J; Chen NB; Guo MZ; Zhao Y; Chen LJ; Liu SR; Yun JP; Guo JY; Wang SY; Wang X; Zhang L; Yue DS; Liao ZX; Lin SH; Long H; Pang QS; Liu H
J Cancer; 2020; 11(20):6114-6121. PubMed ID: 32922551
[No Abstract] [Full Text] [Related]
2. A biomarker-based prediction model for risk of locoregional recurrence in pathologic stage IIIA-N2 non-small cell lung cancer.
Jiang G; Huang J; Cui T; Lin X; Lin G
Int J Clin Exp Pathol; 2020; 13(12):3060-3082. PubMed ID: 33425107
[TBL] [Abstract][Full Text] [Related]
3. Competing risk nomogram predicting initial loco-regional recurrence in gastric cancer patients after D2 gastrectomy.
Wang SB; Qi WX; Chen JY; Xu C; Kirova YM; Cao WG; Cai R; Cao L; Yan M; Cai G
Radiat Oncol; 2019 Jul; 14(1):128. PubMed ID: 31315683
[TBL] [Abstract][Full Text] [Related]
4. Predictive Value of Clinicopathological Factors to Guide Post-Operative Radiotherapy in Completely Resected pN2-Stage III Non-Small Cell Lung Cancer.
Chien JC; Hu YC; Tsai YJ; Chien YT; Feng IJ; Shiue YL
Diagnostics (Basel); 2023 Sep; 13(19):. PubMed ID: 37835838
[No Abstract] [Full Text] [Related]
5. Epidermal growth factor receptor mutations are linked to skip N2 lymph node metastasis in resected non-small-cell lung cancer adenocarcinomas.
Guerrera F; Renaud S; Tabbó F; Voegeli' AC; Filosso PL; Legrain M; Boita M; Schaeffer M; Beau-Faller M; Ruffini E; Falcoz PE; Inghirami G; Oliaro A; Massard G
Eur J Cardiothorac Surg; 2017 Apr; 51(4):680-688. PubMed ID: 28329143
[TBL] [Abstract][Full Text] [Related]
6. Prognostic Factors for Survival After Recurrence in Patients With Completely Resected Lung Adenocarcinoma: Important Roles of Epidermal Growth Factor Receptor Mutation Status and the Current Staging System.
Kudo Y; Shimada Y; Saji H; Kato Y; Yoshida K; Matsubayashi J; Nagase S; Kakihana M; Kajiwara N; Ohira T; Nagao T; Ikeda N
Clin Lung Cancer; 2015 Nov; 16(6):e213-21. PubMed ID: 25986624
[TBL] [Abstract][Full Text] [Related]
7. Association between clinicopathological factors and postoperative radiotherapy in patients with completely resected pathological N2 non-small cell lung cancer.
Xu Y; Li J; Wang J; Hu X; Ma H; Li P; Zheng X; Chen M
Oncol Lett; 2018 Feb; 15(2):2641-2650. PubMed ID: 29434986
[TBL] [Abstract][Full Text] [Related]
8. [Factors influencing survival and recurrence and potential significance of postoperative radiotherapy and adjuvant chemotherapy for stage ⅢA-N2 non-small cell lung cancer].
Han W; Song YZ; He M; Li J; Zhang R; Qiao XY
Zhonghua Zhong Liu Za Zhi; 2016 Nov; 38(11):861-867. PubMed ID: 27998447
[No Abstract] [Full Text] [Related]
9. Role of postoperative radiotherapy after curative resection and adjuvant chemotherapy for patients with pathological stage N2 non-small-cell lung cancer: a propensity score matching analysis.
Kim BH; Kim HJ; Wu HG; Kang CH; Kim YT; Lee SH; Kim DW
Clin Lung Cancer; 2014 Sep; 15(5):356-64. PubMed ID: 24996882
[TBL] [Abstract][Full Text] [Related]
10. Supraclavicular Recurrence in Completely Resected (y)pN2 Non-Small Cell Lung Cancer: Implications for Postoperative Radiotherapy.
Liu L; Zheng Z; Li J; Li Y; Ni J
Front Oncol; 2020; 10():1414. PubMed ID: 32850456
[No Abstract] [Full Text] [Related]
11. Multimodality therapy in subclassified stage IIIA-N2 non-small cell lung cancer patients according to the Robinson classification: heterogeneity and management.
Hofmann HS; Braess J; Leipelt S; Allgäuer M; Klinkhammer-Schalke M; Szoeke T; Grosser C; Pfeifer M; Ried M
J Thorac Dis; 2018 Jun; 10(6):3585-3594. PubMed ID: 30069356
[TBL] [Abstract][Full Text] [Related]
12. Predictors of locoregional outcome in patients receiving neoadjuvant therapy and postmastectomy radiation.
Wright JL; Takita C; Reis IM; Zhao W; Saigal K; Wolfson A; Markoe A; Moller M; Hurley J
Cancer; 2013 Jan; 119(1):16-25. PubMed ID: 22736498
[TBL] [Abstract][Full Text] [Related]
13. A Retrospective Study of Stage I to IIIa Lung Adenocarcinoma After Resection: What Is the Optimal Adjuvant Modality for Patients With an EGFR Mutation?
Lv C; An C; Feng Q; Ma Y; Li S; Wang J; Zhang J; Wang X; Yan S; Fang J; Wang Y; Tan F; Yang Y
Clin Lung Cancer; 2015 Nov; 16(6):e173-81. PubMed ID: 25958850
[TBL] [Abstract][Full Text] [Related]
14. A nomogram for predicting locoregional recurrence in primary breast cancer patients who received breast-conserving surgery after neoadjuvant chemotherapy.
Matsuda N; Hayashi N; Ohde S; Yagata H; Kajiura Y; Yoshida A; Suzuki K; Nakamura S; Tsunoda H; Yamauchi H
J Surg Oncol; 2014 Jun; 109(8):764-9. PubMed ID: 24647874
[TBL] [Abstract][Full Text] [Related]
15. Long-Term Impact of Regional Nodal Irradiation in Patients With Node-Positive Breast Cancer Treated With Neoadjuvant Systemic Therapy.
Stecklein SR; Park M; Liu DD; Valle Goffin JJ; Caudle AS; Mittendorf EA; Barcenas CH; Mougalian S; Woodward WA; Valero V; Sahin AA; Yang WT; Shaitelman SF
Int J Radiat Oncol Biol Phys; 2018 Nov; 102(3):568-577. PubMed ID: 29928946
[TBL] [Abstract][Full Text] [Related]
16. Locoregional failure of postmastectomy patients with 1-3 positive axillary lymph nodes without adjuvant radiotherapy.
Cheng JC; Chen CM; Liu MC; Tsou MH; Yang PS; Jian JJ; Cheng SH; Tsai SY; Leu SY; Huang AT
Int J Radiat Oncol Biol Phys; 2002 Mar; 52(4):980-8. PubMed ID: 11958892
[TBL] [Abstract][Full Text] [Related]
17. Incidence of occult pN2 disease following resection and mediastinal lymph node dissection in clinical stage I lung cancer patients.
Bille A; Woo KM; Ahmad U; Rizk NP; Jones DR
Eur J Cardiothorac Surg; 2017 Apr; 51(4):674-679. PubMed ID: 28200091
[TBL] [Abstract][Full Text] [Related]
18. Prediction of lymph node status in completely resected IIIa/N2 small cell lung cancer: importance of subcarinal station metastases.
Qiao R; Zhong R; Xu J; Zhang Y; Zhang B; Wang S; Lou Y; Chen D; Chang Q; Zhao Y; Han B
J Cardiothorac Surg; 2019 Mar; 14(1):63. PubMed ID: 30925891
[TBL] [Abstract][Full Text] [Related]
19. Factors predictive of locoregional recurrence following neoadjuvant chemotherapy in patients with large operable or locally advanced breast cancer: An analysis of the EORTC 10994/BIG 1-00 study.
Gillon P; Touati N; Breton-Callu C; Slaets L; Cameron D; Bonnefoi H
Eur J Cancer; 2017 Jul; 79():226-234. PubMed ID: 28527420
[TBL] [Abstract][Full Text] [Related]
20. 21-Gene Recurrence Score and Locoregional Recurrence in Node-Positive/ER-Positive Breast Cancer Treated With Chemo-Endocrine Therapy.
Mamounas EP; Liu Q; Paik S; Baehner FL; Tang G; Jeong JH; Kim SR; Butler SM; Jamshidian F; Cherbavaz DB; Sing AP; Shak S; Julian TB; Lembersky BC; Wickerham DL; Costantino JP; Wolmark N
J Natl Cancer Inst; 2017 Jan; 109(4):. PubMed ID: 28122895
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
